Plasma cells are differentiated B-lymphocyte white blood cells capable of secreting immunoglobulin, or antibody. These cells play a significant role in the adaptive immune response, namely, being the main cells responsible for humoral immunity. Without their presence, an individual is said to have agammaglobulinemia and is highly susceptible to recurrent infection. Here the hematopoietic lineage, structure, and function of plasma cells are reviewed, along with the clinical presentations arising from improper plasma cell growth and development.
Plasma cells develop from antigen-activated B lymphocytes in secondary lymphoid organs, such as the spleen and lymph nodes, after antigenic stimulation. Blimp-1, IRF4, and XBP-1 transcription factors are known to be essential for the differentiation of mature B cells into plasma cells. BLIMP-1 and XBP-1 are often viewed as key regulators of plasma cell differentiation with Blimp-1 working upstream of XBP-1. Plasma cell differentiation also has a link to the activation of the unfolded protein response (UPR) signaling pathway. UPR activation aids in the plasma cell’s ability to adapt continually to an ever-changing milieu; though the UPR’s function is still under investigation, the belief is that the UPR plays a role in monitoring immunoglobulin concertation and modulating and/or suppressing immunoglobulin secretion.
The most immature blood cell of plasma cell lineage is the plasmablast. Plasmablasts can proliferate and secrete small amounts of antibodies. The terminally differentiated or mature plasma cells are non-proliferating, are much larger than B cells, and can secrete large amounts of antibodies. During their lifespan of 2 to 3 days, they continuously synthesize and secrete antibodies that have specificity for the antigen that stimulated the plasma cell precursor to proliferate and differentiate. Estimates are that a single plasma cell can secrete hundreds to thousands of antibody molecules per second, a remarkable measure of the power of the immune response for combating pathogens. Plasma cells, as antibody factories, are important contributors to humoral immunity.
Though the production and secretion of antibodies were long thought to be the sole functions of plasma cells, recent studies indicate plasma cell involvement in immune response regulation. Within this capacity, research has found plasma cells to inhibit the development of follicular T-helper cells. Mice devoid of plasma cells, via knock-out of the BLIMP-1 gene, expressed elevated levels of follicular T-helper cells, which, in turn, produce IL-21, a protein critical for the processes of affinity maturation, germinal center longevity and function, and B-lymphocyte terminal differentiation. The elevated IL-21 resulting from the lack of plasma cells could, therefore, alter germinal center activity along with altered fates and/or levels of B-lymphocytes. In contrast, limited follicular T-helper cells and IL-21 appear to elevate a competitive milieu for active germinal center physiology, resulting in enhanced affinity and maturation of B-lymphocytes. Taken together, these findings propose that an antigen-specific negative feedback loop exists, modulating plasma cell production, thus mitigating unnecessary and potentially pathological excess plasma cell numbers.
All plasma cells, albeit normal or malignant, are distinguished by their expression of CD38 and CD138. The former catalyzes synthesis and hydrolysis of cyclic ADP-ribose, resulting in the maintenance of intracellular calcium levels. In contrast, CD138, also known as syndecan-1, allows for the plasma cell to attach to extracellular matrix proteins. Recent research has found that in addition to its role in plasma cell adhesion, CD138 plays a further role in acting as a co-receptor for epithelial growth factor (EGF), particularly in the context of multiple myeloma. Though malignant plasma cells express CD38 and CD138 alongside their normal, non-malignant counterparts, a distinguishing characteristic unique to malignant plasma cells is the loss of CD19 expression alongside the possible aberrant expression of CD56, a marker characteristic of natural killer (NK) cells. It bears mention, however, that not all myeloma cells express CD56.
An additional noteworthy marker of plasma cells is CD79a. The protein plays a critical role in B-lymphocyte antigen signal transduction and overall B-lymphocyte development and stabilization. Though CD79a is present in the cytoplasm of both precursor B-lymphocytes and mature, differentiated plasma cells, its aberrant loss of expression has been noted in certain samples of plasma cell neoplasms.
Plasma cells vary in size from 14 to 20 micrometers. They are round-to-ovoid cells containing abundant deep blue cytoplasm with a pale perinuclear area corresponding to the Golgi apparatus. They have a round, eccentrically placed nucleus with coarse chromatin arranged in clock face (art wheel) pattern. Most plasma cells are uninucleate; few are binucleate or multinucleate. They may contain cytoplasmic inclusions called Russell bodies or multiple spherical inclusions packed in their cytoplasm (Mott, grape, or morular cells). Russell bodies and the inclusions of Mott cells are dilated endoplasmic reticulum cisternae containing condensed immunoglobulins.
Electron microscopy reveals that the plasma cells contain an eccentric round nucleus with condensed chromatin and a well-developed nucleolus. The nuclear membrane-associated chromatin gives the nuclei of mature plasma cells a cartwheel appearance in histologic sections. The cytoplasm contains parallel arrays of rough endoplasmic reticulum, cytoplasmic fibrils, and numerous polymorphic mitochondria. The cytoplasm also contains a Golgi complex immediately adjacent to the nucleus. Intracytoplasmic inclusions of various types—elliptical, round, or needle-like crystalline—are present. A significant accumulation of immunoglobulins forms these inclusions.
Deviation from proper plasma cell proliferation can lead to a number of clinical pathologies. Such classify as plasma cell neoplasms and plasma cell immunodeficiency.
Plasma cell neoplasms are characteristically an aberrant proliferation of clonal plasma cells producing monoclonal, heavy-chain, class-switched immunoglobulin, referred to as M-protein. Contingent on the amount of excessive proliferation and the presence of associated findings induced by such proliferation, plasma cell neoplasms can classify into a number of specified pathological states. Determination of the extent of neoplasm involves a complete diagnostic evaluation, which includes the following specific tests and observations: complete CBC with differential; serum protein electrophoresis (to evaluate for M protein); immunofixation (to determine amount and type of immunoglobulin); serum-free light chain analysis; complete skeletal survey (to assess for the presence of lytic lesions); and a bone marrow biopsy (to determine the percentage of clonal plasma cells and potential cytogenetic analysis).
Plasma Cell Neoplasms
Monoclonal gammopathy of undetermined significance, also known as MGUS, is the least severe manifestation of plasma cell neoplasm. MGUS classifies as a clonal population of plasma cells secreting immunoglobulin, though serum M-protein concentration does not exceed 3 g/dL. Likewise, the clonal plasma cells do not exceed 10% of the bone marrow. Patients are often asymptomatic, and many patients with MGUS do not progress into malignancy. Research has shown the prevalence of MGUS to affect 1% to 2% of the population in the United States and Europe. Men are more often affected than women, and the incidence increases with age. Further, research has identified a higher prevalence in individuals of African descent.
Immunofixation studies of monoclonal protein indicate that approximately 70% of MGUS cases are IgG, 15% are IgM, 12% are IgA, and 3% are biclonal. Contingent on immunoglobulin type, MGUS is often classified into two main types with distinct potential clinical progression. Patients with IgM MGUS may progress to lymphoplasmacytic lymphoma or Waldenström macroglobulinemia. In contrast, the progression of non-IgM MGUS cases manifests as smoldering myeloma or multiple myeloma.
As plasma cells continue to proliferate aberrantly, an individual may progress beyond the criteria of MGUS; a stage defined clinically as smoldering myeloma. In contrast to MGUS, serum M-protein levels are equal to or greater than 3 g/dL, and clonal plasma cells comprise 10% to 59% of the bone marrow. By definition, a patient with smoldering myeloma does not present with CRAB lesions. CRAB lesions demonstrate calcium elevation, renal inefficacy, anemia, and bone disease (lytic lesion(s)). They are a potential manifestation seen in multiple myeloma, as explained in the following subsection.
Similar to MGUS, the presence of criteria for smoldering myeloma manifests asymptomatically. In contrast to MGUS, however, individuals with smoldering myeloma are significantly more likely to progress to the stage of symptomatic multiple myeloma: rate of progression from smoldering myeloma to multiple myeloma is 10% annually for the first five years; 3% annually for the next five years; and 1% each year onward.
The most severe presentation of plasma cell neoplasm is that of multiple myeloma. Though similar to smoldering myeloma in having serum M-protein concentrations of at least 3 g/dL, multiple myeloma criteria require the presence of at least one additional characteristic. Such include the presence of one of more CRAB lesions, bone marrow clonal plasma cells exceeding 60%, a serum-free light chain ratio equal to or greater than 100, and at least one focal lesion detected in MRI.
Multiple myeloma represents approximately 10% of all hematopoietic neoplasms. Symptoms vary from individual-to-individual and range from focal, non-specific signs to systemic involvement. Commonly presenting symptoms include anemia, usually normochromic and normocytic; bone pain, especially in the chest and back; renal failure (elevated creatinine); hypercalcemia; fatigue, infection, and weight loss. Multiple myeloma is, unfortunately, often incurable, ultimately resulting in death attributable infection or renal failure. Median survival ranges from 2.5 to 5 years and is highly variable.
Other Plasma Cell Neoplasms
Amyloidosis classified as the deposition of immunoglobulin light chain fibrils from clonal plasma cells, often of lambda composition. Such can occur independently or as sequelae of MGUS, smoldering myeloma, or multiple myeloma. Deposition of amyloid fibrils most commonly occurs in the kidney, heart, nervous system, and gastrointestinal system. A positive Congo Red stain confirms the presence of amyloid, manifest by a red/pink color under light microscopy and fluorescing as apple-green birefringence when polarized. Additional plasma cell neoplasms include solitary plasmacytoma of bone and extraosseous plasmacytoma.
Plasma Cell Deficiencies
Counter to the preceding disorders, characterized by excessive plasma cells or their byproducts, common variable immunodeficiency (CVID) is the result of a lack of adequate plasma cell numbers. The diagnosis of the disorder is established by reduced levels of IgG, IgA, and/or IgM. Specifically, CVID is noted by an IgG level of < 400 mg/dL. The lack of immunoglobulin results in an increasingly significant susceptibility to bacterial infections. Further, individuals with CVID are prone to several chronic pathologies, including chronic lung disease, inflammatory bowel disease, autoimmune disorders, and lymphoid hyperplasia. As this diagnosis is one that will remain with an individual throughout his or her lifetime, antibody titer to common pathogens (i.e., Haemophilus influenzae, MMR, varicella, and pneumococcus) should have consistent testing. If IgG levels decrease beyond 200 mg/dL, immunoglobulin replacement therapy is the recommendation.
In addition to CVID, over 100 primary immunodeficiencies are attributable to improper B-lymphocyte development and/or function, including improper immunoglobulin production. X-linked agammaglobulinemia (XLA) is characterized by a mutant BTK gene (Bruton’s tyrosine kinase), inhibiting pre-B cell formation. The result is a diminished number of mature B-lymphocytes, including plasma cells, and, therefore, reduced immunoglobulin production and secretion. Given XLA’s inheritance, males are almost exclusively affected. In contrast, selective IgA deficiency (SIGAD), the most common primary immunodeficiency, affects males and females equally. Though the specific mutation associated with SIGAD is not yet fully understood, the disease is known to present in a familial pattern, and the notion of multiple mutations causing SIGAD is under investigation. As implied in the name, patients with selective IgA deficiency lack IgA present in the serum and mucosa; IgM and IgG levels, however, are normal. The condition appears, therefore, to be due to improper isotype switching to IgA and/or improper IgA-secreting B cell maturation. Given the sheer amount of additional primary immunodeficiencies attributable to B-lymphocytes and plasma cells, a continual understanding of these cells’ physiology is crucial for the proper advancement of the health sciences.
|||Shapiro-Shelef M,Lin KI,McHeyzer-Williams LJ,Liao J,McHeyzer-Williams MG,Calame K, Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity. 2003 Oct; [PubMed PMID: 14563324]|
|||Klein U,Casola S,Cattoretti G,Shen Q,Lia M,Mo T,Ludwig T,Rajewsky K,Dalla-Favera R, Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nature immunology. 2006 Jul; [PubMed PMID: 16767092]|
|||Shaffer AL,Lin KI,Kuo TC,Yu X,Hurt EM,Rosenwald A,Giltnane JM,Yang L,Zhao H,Calame K,Staudt LM, Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity. 2002 Jul; [PubMed PMID: 12150891]|
|||Reimold AM,Iwakoshi NN,Manis J,Vallabhajosyula P,Szomolanyi-Tsuda E,Gravallese EM,Friend D,Grusby MJ,Alt F,Glimcher LH, Plasma cell differentiation requires the transcription factor XBP-1. Nature. 2001 Jul 19; [PubMed PMID: 11460154]|
|||Iwakoshi NN,Lee AH,Vallabhajosyula P,Otipoby KL,Rajewsky K,Glimcher LH, Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nature immunology. 2003 Apr; [PubMed PMID: 12612580]|
|||Shaffer AL,Shapiro-Shelef M,Iwakoshi NN,Lee AH,Qian SB,Zhao H,Yu X,Yang L,Tan BK,Rosenwald A,Hurt EM,Petroulakis E,Sonenberg N,Yewdell JW,Calame K,Glimcher LH,Staudt LM, XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity. 2004 Jul; [PubMed PMID: 15345222]|
|||Gass JN,Gifford NM,Brewer JW, Activation of an unfolded protein response during differentiation of antibody-secreting B cells. The Journal of biological chemistry. 2002 Dec 13; [PubMed PMID: 12374812]|
|||Cenci S,Sitia R, Managing and exploiting stress in the antibody factory. FEBS letters. 2007 Jul 31; [PubMed PMID: 17475256]|
|||Pelletier N,McHeyzer-Williams LJ,Wong KA,Urich E,Fazilleau N,McHeyzer-Williams MG, Plasma cells negatively regulate the follicular helper T cell program. Nature immunology. 2010 Dec; [PubMed PMID: 21037578]|
|||Wang X,Hao GL,Wang BY,Gao CC,Wang YX,Li LS,Xu JD, Function and dysfunction of plasma cells in intestine. Cell [PubMed PMID: 30911371]|
|||Bataille R,Jégo G,Robillard N,Barillé-Nion S,Harousseau JL,Moreau P,Amiot M,Pellat-Deceunynck C, The phenotype of normal, reactive and malignant plasma cells. Identification of [PubMed PMID: 16956823]|
|||van de Veen W,Stanic B,Wirz OF,Jansen K,Globinska A,Akdis M, Role of regulatory B cells in immune tolerance to allergens and beyond. The Journal of allergy and clinical immunology. 2016 Sep; [PubMed PMID: 27596706]|
|||Pellat-Deceunynck C,Barillé S,Puthier D,Rapp MJ,Harousseau JL,Bataille R,Amiot M, Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer research. 1995 Aug 15; [PubMed PMID: 7543019]|
|||Tanaka T,Ichimura K,Sato Y,Takata K,Morito T,Tamura M,Kondo E,Ohara N,Yanai H,Sakai M,Takahashi S,Yoshino T, Frequent downregulation or loss of CD79a expression in plasma cell myelomas: potential clue for diagnosis. Pathology international. 2009 Nov; [PubMed PMID: 19883431]|
|||Bortnick A,Murre C, Cellular and chromatin dynamics of antibody-secreting plasma cells. Wiley interdisciplinary reviews. Developmental biology. 2016 Mar-Apr; [PubMed PMID: 26488117]|
|||Kaseb H,Babiker HM, Cancer, Plasma Cell 2020 Jan; [PubMed PMID: 29939690]|
|||Ghobrial IM,Landgren O, How I treat smoldering multiple myeloma. Blood. 2014 Nov 27; [PubMed PMID: 25298034]|
|||Rajkumar SV,Dimopoulos MA,Palumbo A,Blade J,Merlini G,Mateos MV,Kumar S,Hillengass J,Kastritis E,Richardson P,Landgren O,Paiva B,Dispenzieri A,Weiss B,LeLeu X,Zweegman S,Lonial S,Rosinol L,Zamagni E,Jagannath S,Sezer O,Kristinsson SY,Caers J,Usmani SZ,Lahuerta JJ,Johnsen HE,Beksac M,Cavo M,Goldschmidt H,Terpos E,Kyle RA,Anderson KC,Durie BG,Miguel JF, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet. Oncology. 2014 Nov; [PubMed PMID: 25439696]|
|||Castillo JJ, Plasma Cell Disorders. Primary care. 2016 Dec; [PubMed PMID: 27866585]|
|||Landgren O,Gridley G,Turesson I,Caporaso NE,Goldin LR,Baris D,Fears TR,Hoover RN,Linet MS, Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006 Feb 1; [PubMed PMID: 16210333]|
|||Kyle RA,Therneau TM,Rajkumar SV,Offord JR,Larson DR,Plevak MF,Melton LJ 3rd, A long-term study of prognosis in monoclonal gammopathy of undetermined significance. The New England journal of medicine. 2002 Feb 21; [PubMed PMID: 11856795]|
|||Kyle RA,Remstein ED,Therneau TM,Dispenzieri A,Kurtin PJ,Hodnefield JM,Larson DR,Plevak MF,Jelinek DF,Fonseca R,Melton LJ 3rd,Rajkumar SV, Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. The New England journal of medicine. 2007 Jun 21; [PubMed PMID: 17582068]|
|||Cunningham-Rundles C,Maglione PJ, Common variable immunodeficiency. The Journal of allergy and clinical immunology. 2012 May; [PubMed PMID: 22541363]|
|||Smith T,Cunningham-Rundles C, Primary B-cell immunodeficiencies. Human immunology. 2019 Jun; [PubMed PMID: 30359632]|